Maintenance on a high-fat diet impairs the anorexic response to glucagon-like-peptide-1 receptor activation

Physiology and Behavior

Volumn 103, Issue 5, 2011, Pages 557-564

  Williams, Diana L ^a   Hyvarinen, Nina ^a   Lilly, Nicole ^a   Kay, Kristen ^a   Dossat, Amanda ^a   Parise, Eric ^a   Torregrossa, Ann Marie ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

Exendin 4; Glucagon like peptide 1; High fat diet; Obesity; Satiation

Indexed keywords

EXENDIN 3; EXENDIN 4; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LEPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; LIPID DIET; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SATIETY;

ANIMALS; APPETITE DEPRESSANTS; DIETARY FATS; DRUG INTERACTIONS; EATING; GLUCAGON-LIKE PEPTIDE 1; MALE; PEPTIDE FRAGMENTS; PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON; SATIATION; VENOMS;

EID: 79955730918     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2011.04.005     Document Type: Article

References (28)

1. Moran T.H. Gut peptides in the control of food intake. Int J Obes (Lond) 2009, 33(Suppl 1):S7-S10.
2. Hayes M.R., De Jonghe B.C., Kanoski S.E. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 2010, 100:503-510.
3. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
4. Melhorn S.J., Krause E.G., Scott K.A., Mooney M.R., Johnson J.D., Woods S.C., Sakai R.R. Acute exposure to a high-fat diet alters meal patterns and body composition. Physiol Behav 2010, 99:33-39.
5. Farley C., Cook J.A., Spar B.D., Austin T.M., Kowalski T.J. Meal pattern analysis of diet-induced obesity in susceptible and resistant rats. Obes Res 2003, 11:845-851.
6. Primeaux S.D., Barnes M.J., Braymer H.D., Bray G.A. Sensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats. Int J Obes (Lond) 2010, 34:1427-1433.
7. Morrison C.D., Huypens P., Stewart L.K., Gettys T.W. Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity. Biochim Biophys Acta 2009, 1792:409-416.
8. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
9. Anini Y., Brubaker P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 2003, 52:252-259.
10. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., Semjonous N.M., Dakin C.L., Filipsson K., Wang F., Kent A.S., Frost G.S., Ghatei M.A., Bloom S.R. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005, 146:5120-5127.
11. Covasa M., Ritter R.C. Rats maintained on high-fat diets exhibit reduced satiety in response to CCK and bombesin. Peptides 1998, 19:1407-1415.
12. Zheng H., Lenard N.R., Shin A.C., Berthoud H.R. Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. Int J Obes 2009, 33(Suppl 2):S8-S13.
13. Berridge K.C., Ho C.Y., Richard J.M., DiFeliceantonio A.G. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res 2010, 1350:43-64.
14. Nielsen L.L., Young A.A., Parkes D.G. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
15. Talsania T., Anini Y., Siu S., Drucker D.J., Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005, 146:3748-3756.
16. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27:313-318.
17. Pérez-Tilve D., González-Matías L., Alvarez-Crespo M., Leiras R., Tovar S., Diéguez C., Mallo F. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007, 56:143-151.
18. Aviv V., Meivar-Levy I., Rachmut I.H., Rubinek T., Mor E., Ferber S. Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem 2009, 284:33509-33520.
19. Knauf C., Cani P.D., Ait-Belgnaoui A., Benani A., Dray C., Cabou C., Colom A., Uldry M., Rastrelli S., Sabatier E., Godet N., Waget A., Penicaud L., Valet P., Burcelin R. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008, 149:4768-4777.
20. Li L., Yang G., Li Q., Tan X., Liu H., Tang Y., Boden G. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 2008, 10:921-930.
21. Ayala J.E., Bracy D.P., James F.D., Burmeister M.A., Wasserman D.H., Drucker D.J. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 2010, 151:4678-4687.
22. Mack C.M., Moore C.X., Jodka C.M., Bhavsar S., Wilson J.K., Hoyt J.A., Roan J.L., Vu C., Laugero K.D., Parkes D.G., Young A.A. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006, 30:1332-1340.
23. Neary M.T., Batterham R.L. Gut hormones: implications for the treatment of obesity. Pharmacol Ther 2009, 124:44-56.
24. Rüttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
25. Covasa M. Deficits in gastrointestinal responses controlling food intake and body weight. Am J Physiol Regul Integr Comp Physiol 2010, 299:R1423-R1439.
26. Wang J., Obici S., Morgan K., Barzilai N., Feng Z., Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001, 50:2786-2791.
27. Reidelberger R.D., Haver A.C., Apenteng B.A., Anders K.L., Steenson S.M. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 2011, 19:121-127.
28. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.